INTRODUCTION: During the past three decades, improvements in the treatment of childhood leukemia have resulted in high cure rates, particularly for acute lymphoblastic leukemia (ALL). Unfortunately, successful therapy has come with a price, as significant morbidity can result from neurological affects which harm the brain and spinal cord. The expectation and hope is that chemotherapy, as a primary means of CNS therapy, will result in acceptable disease control with less CNS morbidity than has been observed with combinations of chemotherapy and radiotherapy over the past several decades. METHODS AND RESULTS: In this review we discuss the poignant, historical aspects of CNS leukemia therapy, outline current methods of systemic and CNS leukemia therapy, and present imaging findings we have encountered in childhood leukemia patients with a variety of acute neurological conditions. A major objective of our research is to understand the neuroimaging correlates of acute and chronic effects of cancer and therapy. Specific features related to CNS leukemia and associated short-term toxicities, both disease- and therapy-related, are emphasized in this review with the specific neuroimaging findings. Specific CNS findings are similarly important when treating acute myelogenous leukemia (AML), and details of leukemic involvement and toxicities are also presented in this entity. CONCLUSION: Despite contemporary treatment approaches which favor the use of chemotherapy (including intrathecal therapy) over radiotherapy in the treatment of CNS leukemia, children still occasionally experience morbid neurotoxicity. Standard neuroimaging is sufficient to identify a variety of neurotoxic sequelae in children, and often suggest specific etiologies. Specific neuroimaging findings frequently indicate a need to alter antileukemia therapy. It is important to appreciate that intrathecal and high doses of systemic chemotherapy are not innocuous and are associated with acute, specific, recognizable, and often serious neurological consequences.
INTRODUCTION: During the past three decades, improvements in the treatment of childhood leukemia have resulted in high cure rates, particularly for acute lymphoblastic leukemia (ALL). Unfortunately, successful therapy has come with a price, as significant morbidity can result from neurological affects which harm the brain and spinal cord. The expectation and hope is that chemotherapy, as a primary means of CNS therapy, will result in acceptable disease control with less CNS morbidity than has been observed with combinations of chemotherapy and radiotherapy over the past several decades. METHODS AND RESULTS: In this review we discuss the poignant, historical aspects of CNS leukemia therapy, outline current methods of systemic and CNS leukemia therapy, and present imaging findings we have encountered in childhood leukemiapatients with a variety of acute neurological conditions. A major objective of our research is to understand the neuroimaging correlates of acute and chronic effects of cancer and therapy. Specific features related to CNS leukemia and associated short-term toxicities, both disease- and therapy-related, are emphasized in this review with the specific neuroimaging findings. Specific CNS findings are similarly important when treating acute myelogenous leukemia (AML), and details of leukemic involvement and toxicities are also presented in this entity. CONCLUSION: Despite contemporary treatment approaches which favor the use of chemotherapy (including intrathecal therapy) over radiotherapy in the treatment of CNS leukemia, children still occasionally experience morbid neurotoxicity. Standard neuroimaging is sufficient to identify a variety of neurotoxic sequelae in children, and often suggest specific etiologies. Specific neuroimaging findings frequently indicate a need to alter antileukemia therapy. It is important to appreciate that intrathecal and high doses of systemic chemotherapy are not innocuous and are associated with acute, specific, recognizable, and often serious neurological consequences.
Authors: C D Bloomfield; C Shuma; L Regal; P P Philip; D K Hossfeld; A M Hagemeijer; O M Garson; B A Peterson; M Sakurai; G Alimena; R Berger; J D Rowley; T Ruutu; F Mitelman; G W Dewald; J Swansbury Journal: Cancer Date: 1997-12-01 Impact factor: 6.860
Authors: E L Sievers; B J Lange; J D Buckley; F O Smith; D A Wells; C A Daigneault-Creech; K E Shults; I D Bernstein; M R Loken Journal: J Natl Cancer Inst Date: 1996-10-16 Impact factor: 13.506
Authors: Y Ravindranath; A M Yeager; M N Chang; C P Steuber; J Krischer; J Graham-Pole; A Carroll; S Inoue; B Camitta; H J Weinstein Journal: N Engl J Med Date: 1996-05-30 Impact factor: 91.245
Authors: Liron Frishman-Levy; Avishai Shemesh; Allan Bar-Sinai; Chao Ma; Zhenya Ni; Shahar Frenkel; Vera Muench; Hilke Bruckmueller; Christian Vokuhl; Klaus-Michael Debatin; Cornelia Eckert; Martin Stanulla; Martin Schrappe; Kerry S Campbell; Ron Loewenthal; Denis M Schewe; Jacob Hochman; Lueder H Meyer; Dan Kaufman; Gunnar Cario; Angel Porgador; Shai Izraeli Journal: Blood Date: 2015-04-20 Impact factor: 22.113
Authors: Nina S Kadan-Lottick; Pim Brouwers; David Breiger; Thomas Kaleita; James Dziura; Veronika Northrup; Lu Chen; Megan Nicoletti; Bruce Bostrom; Linda Stork; Joseph P Neglia Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Zsila S Sadighi; Kirsten K Ness; Melissa M Hudson; E Brannon Morris; Davonna S Ledet; Ching-Hon Pui; Scott C Howard; Kevin R Krull; Emily Browne; Debbie Crom; Pamela S Hinds; Liang Zhu; Deokumar Srivastava; Raja B Khan Journal: Eur J Paediatr Neurol Date: 2014-07-05 Impact factor: 3.140
Authors: Nirav Patel; Benjamin J RIch; Shareen Patel; Justin M Watts; Ronald Benveniste; Matthew Abramowitz; Arnold Markoe; Daniel G Eichberg; Ricardo J Komotar; Marcarena De La Fuente; Joshua Pasol; Tejan Diwanji Journal: Cureus Date: 2021-05-24